The study does not provide near-term revenue catalysts but strengthens the differentiation narrative for acoramidis versus competitors (e.g., tafamidis). Monitor ESC Congress 2026 for additional CMR data. Approval and market access for Attruby are already established; this study supports label expansion and long-term value creation.
Price Chart
Executive Summary
BridgeBio announced first patient dosed in ASCEND-ATTR, a Phase 3b/4 study of acoramidis in ATTR-CM, designed to assess long-term effects on cardiac structure, function, and amyloid burden. This builds on encouraging CMR substudy data from the Phase 3 ATTRibute-CM trial suggesting potential disease reversal. The study is prospective and open-label, enrolling ~150 patients with annual imaging over 36 months.
Key Facts
- First participant dosed in ASCEND-ATTR, a Phase 3b/4 open-label study of acoramidis in ATTR-CM
- Study will enroll ~150 participants with annual CMR and echocardiography over 36 months
- Primary endpoint: responder status at Month 36 by CMR based on improvement in LV systolic function
- Acoramidis is the only oral, near-complete (≥90%) TTR stabilizer approved (Attruby) for ATTR-CM
- Prior CMR substudy of ATTRibute-CM suggested improvement in LVMi, LVSVi, LVEF and evidence of amyloid regression
- Additional data from ATTRibute-CM CMR substudy and OLE to be shared at ESC Congress 2026
Financial Impact
Phase 3b/4 study initiation — no financial impact disclosed; acoramidis is already approved and commercialized for ATTR-CM
Risk Factors
- Single-arm, open-label design limits definitive conclusions versus placebo or active comparator
- Enrollment and 36-month follow-up timeline reduces near-term impact
- Risk that positive CMR substudy findings are not replicated in this larger, prospective study
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3351235 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 31, 2026 4w ago | 8-K | $76.59 $65.97 | ▼ −13.87% | ▼ −13.68% | $67.47 (−11.90%) |
Aug 26, 2026 5w ago | Press Release | $79.37 $66.28 | ▼ −16.49% | ▼ −16.72% | $67.47 (−14.99%) |
Aug 22, 2026 5w ago | Institutional Cluster | $81.07 $69.23 | ▼ −14.60% | ▼ −15.92% | $67.47 (−16.77%) |
Aug 17, 2026 6w ago | 8-K | $79.89 $72.38 | ▼ −9.40% | ▼ −7.87% | $67.47 (−15.54%) |
Aug 13, 2026 7w ago | Press Release | $79.86 $72.38 | ▲ +9.37% | ▲ +7.38% | $67.47 (+15.51%) |
Aug 10, 2026 7w ago | 8-K | $84.67 $76.08 | ▼ −10.15% | ▼ −9.09% | $67.47 (−20.31%) |
Aug 10, 2026 7w ago | Press Release | $84.67 $76.08 | ▼ −10.15% | ▼ −9.09% | $67.47 (−20.31%) |
Jul 13, 2026 11w ago | Insider Cluster | $83.08 $84.67 | ▲ +1.91% | ▼ −1.27% | $67.47 (−18.78%) |
Jun 28, 2026 13w ago | Press Release | $72.01 $84.02 | ▲ +16.68% | ▲ +16.96% | $67.47 (−6.30%) |
Jun 24, 2026 14w ago | 144 | $69.69 $82.93 | ▲ +19.00% | ▲ +18.47% | $67.47 (−3.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access